Skip to content
Screener

Immunome IMNM Q2 2026 earnings

Reported August 11, 2026 · After market close

Revenue-
EPS-$0.65Miss by $0.14
EPS estimate-$0.51
“For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch. We are also continuing to advance our broader pipeline, with three additional clinical-stage programs now enrolling patients. We believe this momentum positions us well for a milestone-rich second half of 2026.”
Clay B. Siegall

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$181.8K
EPS estimate-$0.64

Financials

Q2 2026

Income statement

See full
Revenue--100%
Operating income-$78.1M-68.1%
Net income-$73.1M-68.5%
EPS (diluted)-$0.65-30.0%

Balance sheet

See full
Cash & equivalents$217.7M+51.3%
Total debt$4.7M+14.4%
Total equity$525.1M+95.0%
Total assets$565.4M+90.8%

Cash flow

See full
Operating cash flow-$61.7M-24.9%
CapEx$2.2M+140%
Free cash flow-$63.9M-27.0%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$3.27B+277%
Enterprise value$3.05B+320%

Returns & leverage

See full
Return on equity-64%-11.2pp
Debt / equity0×0.0×
Current ratio15.1×+3.0×

FAQ

When did Immunome report Q2 2026 earnings?
Immunome (IMNM) reported Q2 2026 earnings on August 11, 2026 after market close.
What were Immunome's Q2 2026 revenue and EPS?
Immunome reported revenue of - and eps of $-0.65 for Q2 2026.
Did Immunome beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.51 by $0.14.
How did Immunome's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $4.0M a year earlier and eps declined 30.0% from $-0.50.
Where can I find Immunome's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-344577) and the 10-Q periodic report (0001193125-26-344636) directly on SEC EDGAR. The filing index links above go to sec.gov.